insulin ( latin insula , `` island '' , produc islet langerhan pancrea ) polypeptid hormon regul carbohydr metabol . apart primari effector carbohydr homeostasi , effect fat metabol chang liver 's abil releas fat store . insulin 's concentr extrem widespread effect throughout bodi . insulin use medic form diabet mellitu . patient type 1 diabet mellitu depend exogen insulin ( commonli inject subcutan ) surviv absolut defici hormon ; patient type 2 diabet mellitu either rel low insulin product insulin resist , non-trivi fraction type 2 diabet eventu requir insulin administr medic becom inadequ control blood glucos level . insulin molecular weight 5808 da . molecular formula c 257 h 383 n 65 77 6 . insulin structur vari slightli speci anim . carbohydr metabol regulatori function strength human also vari . porcin ( pig ) insulin particularli close human ' . # # discoveri character 1869 paul langerhan , medic student berlin , studi structur pancrea microscop notic previously-unidentifi cell scatter exocrin tissu . function `` littl heap cell , '' later known islet langerhan , unknown , edouard laguess later argu may produc secret play regulatori role digest . 1889 , polish-german physician oscar minkowski collabor joseph von mehr remov pancrea healthi dog demonstr assum role digest . sever day dog 's pancrea remov , minkowski 's anim keeper notic swarm fli feed dog 's urin . test urin found sugar dog 's urin , demonstr first time relationship pancrea diabet . 1901 , anoth major step taken eugen opi , clearli establish link islet langerhan diabet : diabet mellitu .... caus destruct islet langerhan occur bodi part wholli destroy . demonstr , link pancrea diabet clear , specif role islet . next two decad , sever attempt made isol secret islet potenti treatment . 1906 georg ludwig zuelzer partial success treat dog pancreat extract , unabl continu work . 1911 1912 , e.l. scott univers chicago use aqueou pancreat extract note slight diminut glycosuria , unabl convinc director research shut . israel kleiner demonstr similar effect rockefel univers 1919 , work interrupt world war unabl return . nicola paulescu , professor physiolog romanian school medicin , publish similar work 1921 carri franc patent romania , argu ever sinc right discover . howev , nobel prize committe 1923 credit practic extract insulin team univers toronto . octob 1920 , frederick bant read one minkowski 's paper conclud digest secret minkowski origin studi break secret , therebi make imposs extract success . jot note ligat pancreat duct dog . keep dog aliv till acinu degener leav islet . tri isol intern secret reliev glycosurea . travel toronto meet j.j.r . macleod , entir impress idea . nevertheless , suppli bant lab univers , assist , medic student charl best , ten dog , left vacat summer 1921 . method tie ligatur ( string ) around pancreat duct , , examin sever week later , pancreat digest cell die absorb immun system , leav thousand islet . isol protein islet produc call isletin . bant best abl keep pancreatectom dog aliv summer . macleod saw valu research return europ , demand re-run prove method actual work . sever week later clear second run also success , help publish result privat toronto novemb . howev , need six week extract isletin , dramat slow test . bant suggest tri use fetal calf pancrea , yet develop digest gland ; reliev find method work well . suppli problem solv , next major effort purifi protein . decemb 1921 , macleod invit biochemist jame collip help task , , within month , felt readi test . januari 11 , 1922 , leonard thompson , fourteen-year-old diabet , given first inject insulin . howev , extract impur suffer sever allerg reaction , inject cancel . next 12 day , collip work day night improv extract , second dose inject 23rd . complet success , obviou side-effect , complet elimin symptom diabet . howev , bant best never work well collip , regard someth interlop , collip left soon . spring 1922 , best manag improv techniqu point larg quantiti insulin could extract demand , extract remain impur . howev , approach eli lilli compani offer help shortli first public 1921 , took lilli offer april . novemb , lilli made major breakthrough , abl produc larg quantiti pure insulin . insulin offer sale shortli thereaft . # # nobel prize macleod bant award nobel prize physiolog medicin 1923 discoveri insulin . bant , insult best mention , share prize best , macleod immedi share collip . patent insulin sold univers toronto one dollar . exact sequenc amino acid compris insulin molecul , so-cal primari structur , determin british molecular biologist frederick sanger . first protein structur complet determin . award nobel prize chemistri 1958 . 1967 , decad work , dorothi crowfoot hodgkin determin spatial conform molecul , mean x-ray diffract studi . award nobel prize chemistri 1964 develop crystallographi . rosalyn sussman yalow receiv 1977 nobel prize medicin develop radioimmunoassay insulin . # # structur product insulin highli conserv across anim kingdom ; ancient molecul . c. elegan , nematod worm , us insulin much way vertebr . within vertebr , simular insulin close . bovin insulin differ human three amino acid residu , porcin insulin one . even insulin speci fish similiar enough human effect human . mammal , insulin synthes pancrea within beta cell ( β-cell ) islet langerhan . one three million islet langerhan ( pancreat islet ) form endocrin part pancrea , primarili exocrin gland . endocrin portion account 2 % total mass pancrea . within islet langerhan , beta cell constitut 60–80 % cell . beta cell , insulin synthes proinsulin precursor molecul action proteolyt enzym known prohormon convertas ( pc1 pc2 ) , well exoproteas carboxypeptidas e. modif proinsulin remov centr portion molecul , c-peptid , c- n- termin end proinsulin . remain polypeptid ( 51 amino acid total ) , b- a- chain , bound togeth disulfid bond . confusingli , primari sequenc proinsulin go order `` b-c-a '' , sinc b chain identifi basi mass , c peptid discov other . # # action cellular metabol level action insulin global human metabol level includ : control cellular intak certain substanc , promin glucos muscl adipos tissu ( ⅔ bodi cell ) . increas dna replic protein synthesi via control amino acid uptak . modif activ numer enzym ( alloster effect ) . action insulin cell includ : increas glycogen synthesi – insulin forc storag glucos liver ( muscl ) cell form glycogen ; lower level insulin caus liver cell convert glycogen glucos excret blood . clinic action insulin directli use reduc high blood glucos level diabet . increas fatti acid synthesi – insulin forc fat cell take blood lipid convert triglycerid ; lack insulin caus revers . increas esterif fatti acid – forc adipos tissu make fat ( ie , triglycerid ) fatti acid ester ; lack insulin caus revers . decreas proteinolysi – forc reduct protein degrad ; lack insulin increas protein degrad . decreas lipolysi – forc reduct convers fat cell lipid store blood fatti acid ; lack insulin caus revers . decreas gluconeogenesi – decreas product glucos variou substrat liver ; lack insulin caus glucos product assort substrat liver elsewher . increas amino acid uptak – forc cell absorb circul amino acid ; lack insulin inhibit absorpt . increas potassium uptak – forc cell absorb serum potassium ; lack insulin inhibit absorpt . arteri muscl tone – forc arteri wall muscl relax , increas blood flow , especi micro arteri ; lack insulin reduc flow allow muscl contract . # # regulatori action blood glucos despit long interv meal occasion consumpt meal substanti carbohydr load ( e.g. , half birthday cake bag potato chip ) , human blood glucos level normal remain within narrow rang . human vari 70 mg/dl perhap 110 mg/dl ( 3.9 6.1 mmol/litr ) except shortli eat blood glucos level rise temporarili . homeostat effect result mani factor , hormon regul import . usual surpris realiz littl glucos actual maintain blood , bodi fluid . control mechan work small quantiti . healthi adult male 75 kg blood volum 5 litr , blood glucos level 100 mg/dl 5.5 mmol/l correspond 5 g ( 1/5 ounc ) glucos blood approxim 45 g ( 1½ ounc ) total bodi water ( obvious includ mere blood usual 60 % total bodi weight men ) . familiar comparison may help -- 5 gram glucos equival commerci sugar packet ( provid mani restaur coffe tea ) . two type mutual antagonist metabol hormon affect blood glucos level : catabol hormon ( glucagon , growth hormon , catecholamin ) , increas blood glucos one anabol hormon ( insulin ) , decreas blood glucos mechan restor satisfactori blood glucos level hypoglycemia must quick , effect , immedi seriou consequ insuffici glucos ( extrem , coma , less immedi danger , confus unsteadi , amongst mani effect ) . , least short term , far danger littl glucos blood much . healthi individu mechan inde gener effici , symptomat hypoglycemia gener found diabet use insulin pharmacolog treatment . hypoglycem episod vari greatli person time time , sever swift onset . sever case prompt medic assist essenti , damag ( brain tissu ) even death result suffici low blood glucos level . beta cell islet langerhan sensit variat blood glucos level follow mechan ( see figur right ) : glucos enter beta cell glucos transport glut2 glucos go glycolysi respiratori cycl multipl high-energi atp molecul produc oxid depend blood glucos level henc atp level , atp control potassium channel ( k + ) close cell membran depolar depolaris , voltag control calcium channel ( ca 2+ ) open calcium flow cell increas calcium level caus activ phospholipas c , cleav membran phospholipid phosphatidyl inositol 4,5-bisphosph inositol 1,4,5-triphosph diacylglycerol . inositol 1,4,5-triphosph ( ip3 ) bind receptor protein membran endoplasm reticulum ( er ) . allow releas ca 2+ er via ip3 gate channel , rais cell concentr calcium . significantli increas amount calcium cell caus releas previous synthesis insulin , store secretori vesicl calcium level also regul express insulin gene via calcium respons element bind protein ( creb ) . main mechan releas insulin regul insulin synthesi . addit insulin synthesi releas take place gener food intak , glucos carbohydr intak , beta cell also somewhat influenc autonom nervou system . signal mechan control fulli understood . substanc known stimul insulin releas acetylcholin , releas vagu nerv end ( parasympathet nervou system ) , cholecystokinin , releas enteroendocrin cell intestin mucosa gastrointestin inhibitori peptid ( gip ) . first act similarli glucos phospholipas c , last act mechan adenyl cyclas . sympathet nervou system ( via α 2 -adrenerg agonist norepinephrin ) inhibit releas insulin . glucos level come usual physiolog valu , insulin releas beta cell slow stop . blood glucos level drop lower , especi danger low level , releas hyperglycem hormon ( promin glucagon islet langerhan ' alpha cell ) forc releas glucos blood cellular store , primarili liver cell store glycogen . releas insulin strongli inhibit stress hormon norepinephrin ( noradrenalin ) , lead increas blood glucos level stress . # # signal transduct special transport protein cell membran glucos blood enter cell . transport , indirectli , insulin control certain bodi cell type ( eg , muscl cell ) . low level circul insulin , absenc , prevent glucos enter cell ( eg , untreat type 1 diabet ) . howev , commonli decreas sensit cell insulin ( eg , reduc insulin sensit characterist type 2 diabet ) , result decreas glucos absorpt . either case , 'cell starvat ' , weight loss , sometim extrem . case , defect releas insulin pancrea . either way , effect , characterist , : elev blood glucos level . activ insulin receptor lead intern cellular mechan directli affect glucos uptak regul number oper protein molecul cell membran transport glucos cell . gene specifi protein make insulin receptor cell membran identifi structur interior , cell membran section , , final decad , extra-membran structur receptor ( australian research announc work 2q 2006 ) . two type tissu strongli influenc insulin , far stimul glucos uptak concern : muscl cell ( myocyt ) fat cell ( adipocyt ) . former import central role movement , breath , circul , etc , latter accumul excess food energi futur need . togeth , account ⅔ cell typic human bodi . # # hypoglycemia although cell use fuel ( promin fatti acid ) , neuron depend glucos sourc energi non-starv human . requir insulin absorb glucos , unlik muscl adipos tissu , small intern store glycogen . glycogen store liver cell ( unlik glycogen store muscl cell ) convert glucos , releas blood , glucos digest low absent , glycerol backbon triglycerid also use produc blood glucos . exhaust sourc , either temporarili sustain basi , reduc blood glucos suffici low level , first dramat manifest impair function central nervou system – dizzi , speech problem , even loss conscious , unknown . known hypoglycemia , case produc unconsci , `` hypoglycem coma '' ( formerli term `` insulin shock '' common caus agent ) . endogen caus insulin excess ( insulinoma ) rare , overwhelm major hypoglycemia case caus human action ( e.g . iatrogen , caus medicin ) , usual accident . report case murder , attempt murder suicid use insulin overdos , insulin shock appear due mismanag insulin ( n't eat much anticip , exercis expect ) , mistak ( e.g . 20 unit insulin instead 2 ) . possibl caus hypoglycemia includ : oral hypoglycem agent ( e.g. , sulfonylurea , similar drug , increas insulin releas beta cell respons particular blood glucos level ) . extern insulin ( usual inject subcutan ) . ingest low-carbohydr sugar substitut ( anim studi show trigger insulin releas accord report discov magazin august 2005 , p18 ) . # # diseas syndrom sever condit insulin disturb patholog : diabet mellitu – gener term refer state character hyperglycemia . type 1 – autoimmune-medi destruct insulin produc beta cell pancrea result absolut insulin defici . type 2 – multifactor syndrom combin influenc genet suscept influenc environment factor , best known obes , age , physic inact , result insulin resist cell requir insulin glucos absorpt . form diabet strongli inherit . type impair glucos toler ( see diabet articl ) . insulinoma reactiv hypoglycemia . metabol syndrom – precondit first call metabol syndrom x gerald reaven , sometim call prediabet . character elev blood pressur , dyslipidemia ( disturb blood cholesterol form blood lipid ) , increas waist circumfer ( least popul much develop world ) . basic underli caus insulin resist , diminish capac insulin respons tissu ( eg , muscl , fat , liver ) respond insulin . untreat , metabol syndrom lead morbid essenti hypertens , obes , type 2 diabet , cardiovascular diseas ( cvd ) . polycyst ovari syndrom – complex syndrom woman reproduct year anovul androgen excess commonli display hirsut . mani case pco insulin resist present . # # medic # # # principl insulin absolut requir anim ( includ human ) life . mechan almost ident nematod worm ( e.g . c. elegan ) , fish , mammal . human , insulin depriv due remov destruct pancrea lead death day week . insulin must administ patient lack hormon , , reason . clinic , call diabet mellitu type 1 . initi sourc insulin clinic use human cow , hors , pig fish pancrea . insulin sourc effect human nearli ident human insulin ( three amino acid differ bovin insulin , one amino acid differ porcin ) . insulin obvious protein strongli conserv across evolutionari time . differ suitabl beef , pork , fish insulin prepar particular patient primarili result prepar puriti allerg reaction assort non-insulin substanc remain prepar . puriti improv less steadili sinc 1920 , allerg reaction continu though slowli reduc sever . insulin product anim pancrea widespread decad , patient today reli insulin sourc . human insulin manufactur widespread clinic use use genet engin techniqu , significantli reduc impur reaction problem . eli lilli market first insulin , humulin , 1982 . humulin first medic produc use modern genet engin techniqu , actual human dna insert host cell ( e. coli case ) . host cell allow grow reproduc normal , due insert human dna , produc actual human insulin . genentech develop techniqu lilli use produc humulin . novo nordisk also develop genet engin insulin independ . insulin use clinic produc way , avoid allerg reaction problem . sinc januari 2006 , insulin distribut u.s. countri human insulin analog . special fda import process requir obtain beef pork insulin use u.s. , though may remain stock pork insulin made lilli 2005 earlier . # # # mode administr unlik mani medicin , insulin taken oral ; like protein gastrointestin tract , reduc amino acid compon , whereupon 'insulin activ ' lost . research underway develop method protect insulin taken oral , none yet reach clinic use . instead insulin usual taken subcutan inject single-us syrinx needl , insulin pump repeated-us insulin pen needl . sever problem insulin clinic treatment diabet : mode administr . select 'right ' dose time . select appropri insulin prepar ( typic 'speed onset durat action ' ground ) . adjust dosag time fit food amount type . adjust dosag time fit exercis undertaken . adjust dosag , type , time fit condit instanc increas stress ill . dosag non-physiolog subcutan bolu dose insulin alon administ instead combin insulin c-peptid releas gradual directli portal vein . simpli nuisanc patient inject sever time day . may danger case mistak ( especi 'too much ' insulin ) . attempt improv upon mode administ insulin , mani peopl find inject awkward pain . one altern jet inject ( also sometim use vaccin ) , differ insulin deliveri peak durat compar needl inject . diabet find control possibl jet injector , hypoderm inject . also 'insulin pump ' variou type 'electr injector ' attach semi-perman implant needl ( i.e . cathet ) . achiev adequ glucos control convent inject ( sometim jet inject ) abl appropri pump . insulin pump reason solut . howev limit - cost , potenti hypoglycem episod , cathet problem , , far , approv mean control insulin deliveri field base current blood glucos level . much insulin deliv , patient eat less normal , hypoglycemia . hand , littl insulin deliv , hyperglycemia . lead life-threaten condit . addit , indwel cathet pose risk infect ulcer . howev , risk minim keep cathet site clean . thu far , insulin pump requir care effort use correctli . howev , diabet abl keep glucos reason control pump . research produc watch-lik devic test blood glucos level skin administ correct do insulin pore skin . electr ultrasound found make skin temporarili porou . insulin administr aspect remain experiment , blood glucos test aspect 'wrist applianc ' commerci avail . anoth 'improv ' would avoid period insulin administr self-regul insulin sourc , instanc , pancreat , beta cell , transplant . transplant entir pancrea ( individu organ ) difficult , common . gener , perform conjunct liver kidney transplant . howev , transplant pancreat beta cell possibl . highli experiment ( read 'prone failur ' ) mani year , research alberta , canada , develop techniqu high initi success rate ( 90 % one group ) . beta cell transplant may becom practic common near futur . addit , research explor possibl transplant genet engin non-beta cell secret insulin . clinic testabl result far realiz . sever non-transpl method automat insulin deliveri develop research lab , none close clinic approv . inhal insulin investig , sever insulin administr techniqu . current inhal insulin approv food drug administr exubera . inhal insulin shown similar efficaci inject insulin , term control glucos level blood half-lif . patient switch inject inhal insulin , signific differ found hba1c level three month . patient show signific weight gain pulmonari function length trial , compar baselin . howev follow commerci launch 2005 uk , ( juli 2006 ) recommend nation institut health clinic excel routin use , except case `` proven inject phobia diagnos psychiatrist psychologist '' . sever clinic studi report greater patient satisfact compar subcutan insulin type 1 type 2 diabet . addit method administr insulin diabet pulsatil insulin . method insulin puls patient , mimick physiolog secret insulin pancrea . # # # dosag time central problem requir extern insulin pick right dose insulin right time . physiolog regul blood glucos , non-diabet , would best . increas blood glucos level meal stimulu prompt releas insulin pancrea . increas insulin level caus glucos absorpt storag cell , reduc glycogen glucos convers , reduc blood glucos level , reduc insulin releas . result blood glucos level rise somewhat eat , within hour return normal 'fast ' level . even best diabet treatment human insulin , howev administ , fall short normal glucos control non-diabet . complic matter composit food eaten ( see glycem index ) affect intestin absorpt rate . glucos food absorb ( less ) rapidli amount glucos food . , fat protein caus delay absorpt glucos carbohydr eaten time . well , exercis reduc need insulin even factor remain , sinc work muscl abil take glucos without help insulin . , principl , imposs know certain much insulin ( type ) need 'cover ' particular meal order achiev reason blood glucos level within hour two eat . non-diabet ' beta cell routin automat manag continu glucos level monitor insulin releas . decis diabet must base experi train ( ie , direct physician pa , place specialist diabet educ ) , , specif base individu experi patient . straightforward never done habit routin , care done quit success practic . exampl , diabet requir insulin drink skim milk take equival amount fat , protein , carbohydr , fluid form . particular reaction skim milk differ diabet ' , amount whole milk like caus still differ reaction even person . whole milk contain consider fat skim milk much less . continu balanc act diabet , especi take insulin . insulin depend diabet requir base level insulin ( basal insulin ) , well extra short act insulin cope meal ( bolu insulin ) . maintain basal rate bolu rate continu balanc act insulin diabet manag day . normal achiev regular blood test , although work undertaken continu blood sugar test equip . import notic diabet gener need insulin usual -- less -- physic stress like infect surgeri . # # # type medic prepar insulin ( major supplier — eli lilli novo nordisk — ) never 'insulin water ' . clinic insulin special prepar mixtur insulin plu substanc . delay absorpt insulin , adjust ph solut reduc reaction inject site , . insulin molecul insulin analog slightli modifi : absorb rapidli enough mimic real beta cell insulin ( lilli 's lispro , novo nordisk 's aspart ) . steadili absorb inject instead 'peak ' follow less rapid declin insulin action ( novo nordisk ' version insulin detemir aventi ' version insulin glargin ) . retain insulin action human bodi . manag choos insulin type dosag / time done experienc medic profession work diabet . allow blood glucos level rise , though level caus acut hyperglycem symptom , sensibl choic . sever larg , well design , long term studi conclus shown diabet complic decreas markedli , linearli , consist blood glucos level approach 'normal ' pattern long period . short , diabet close control blood glucos level ( ie , averag , day week , avoid high peak meal ) rate diabet complic go . glucos level close control , rate even approach 'normal ' . chronic diabet complic includ cerebrovascular accid ( cva stroke ) , heart attack , blind ( prolif diabet retinopathi ) , vascular damag , nerv damag diabet neuropathi , kidney failur diabet nephropathi . studi demonstr beyond doubt , possibl patient , so-cal intens insulinotherapi superior convent insulinotherapi . howev , close control blood glucos level ( intens insulinotherapi ) requir care consider effort , hypoglycemia danger fatal . good measur long term diabet control ( approxim 90 day peopl ) serum level glycosyl hemoglobin ( hba1c ) . shorter term integr measur ( two week ) so-cal fructosamin level , measur similarli glyclosyl protein ( chiefli albumin ) shorter half life blood . commerci meter avail measur level field . commonli use type insulin : quick-act , insulin lispro -- begin work within 5 15 minut activ 3 4 hour . short-act , regular insulin -- start work within 30 minut activ 5 8 hour . intermediate-act , nph , lent insulin -- start work 1 3 hour activ 16 24 hour . long-act , ultralent insulin -- start work 4 6 hour , activ 24 28 hour , insulin glargin insulin detemir -- start work within 1 2 hour continu activ , without peak dip , 24 hour . mixtur nph regular insulin -- start work 30 minut activ 16 24 hour . sever variat differ proport mix insulin . # # # abus report patient abus insulin inject larger do lead mild hypoglycem state . extrem danger . sever acut prolong hypoglycemia result brain damag death . juli 23 , 2004 , news report claim former spous promin intern track athlet said , among drug , ex-spous use insulin way 'energ ' bodi . intend implic would seem insulin effect similar alleg steroid . ; eighti year insulin use given reason believ could respect perform enhanc non diabet . improperli treat diabet , sure , prone other exhaust tired , case , proper administr insulin reliev symptom . howev , insulin , chemic clinic , steroid , use non diabet danger alway abus outsid well-equip medic facility. '' game shadow , '' report mark fainaru-wada lanc william , includ alleg san francisco giant , barri bond , use insulin appar belief would increas effect growth hormon ( also alleg ) take . top , non-prescrib insulin ban drug olymp global competit . # # timelin 1922 bant best use bovin insulin extract human 1923 eli lilli produc commerci quantiti bovin insulin 1923 hagedorn found nordisk insulinlaboratorium denmark -- forerunn novo nordisk 1926 nordisk receiv danish charter produc insulin non profit 1936 canadian d.m . scott , a.m. fisher formul zinc insulin mixtur licens novo 1936 hagedorn discov ad protamin insulin prolong effect insulin 1946 nordisk formul isophane® porcin insulin aka neutral protamin hagedorn nph insulin 1946 nordisk crystal protamin insulin mixtur 1950 nordisk market nph insulin 1953 novo formul lente® porcin bovin insulin ad zinc longer last insulin 1973 purifi monocompon ( mc ) insulin introduc 1978 genentech produc human insulin escheria coli bacteria use recombin dna 1981 novo nordisk chemic enzymat convert bovin human insulin 1982 genentech human insulin ( ) approv 1983 eli lilli produc recombin human insulin , humulin® 1985 axel ullrich sequenc human insulin receptor 1988 novo nordisk produc recombin human insulin 1996 lilli humalog® `` lyspro '' insulin analogu approv 2004 aventi lantus® `` glargin '' insulin analogu approv clinic use 2006 novo nordisk levemir® `` detemir '' approv clincal use us .